There were 2 studies only using the normal healthy samples as the control group significantly increased the ability of anti-p53 antibody in the diagnosis of HCC in different liver diseases.[26,28] In addition, it can be seen in the study of tumor grade (only 7 studies) that the diagnostic efficacy of anti-p53 in patients with primary hepatocellular carcinoma was slightly higher than that in late stage, but the difference between them was not obvious. Here, TP53 is linked to liver disorder.